At touchHAEMATOLOGY we aim to support early career haematologists and oncologists. In this video a global leader in the field of multiple myeloma, María-Victoria Mateos, shares her advice on stating a successful career in this specialty. Disclosures: María-Victoria Mateos discloses the following –  Advisory Board or panel fees from Abbvie, Adaptive, Amgen, Celgene, GlaxoSmithKline, Genentech, Janssen, […]

Momelotinib, a small-molecule oral inhibitor of the JAK1/JAK2 kinases was investigated in the phase 3 MOMENTUM study in patients with anaemic myelofibrosis (ClinicalTrials.gov Identifier: NCT04173494). touchHAEMATOLOGY were delighted to talk with Dr. Srdan Verstovsek (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the mechanism of action of momelotinib, the findings […]

Myelofibrosis is a myeloproliferative disorder that leads to severe anaemia and splenomegaly, there is an unmet need for targeting anaemia in the current treatment options for myelofibrosis. In this touchHAEMATOLOGY interview, we spoke with Dr. Srdan Verstovsek (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) around the main challenges of managing myelofibrosis-related […]

CAR-T cell therapy and bispecifics in the treatment of lymphoma: Updates from ASH 2022 Prof. Swaminathan Iyer (University of Texas MD Anderson Cancer Center) reviews the latest data around CAR-T cell therapy and bispecific antibodies presented at ASH 2022. Further information: Abstract 655 entitled ‘Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy […]

The role of transplant and biologics in mantle cell lymphoma In the first of two updates from ASH 2022, Swaminathan Iyer (University of Texas MD Anderson Cancer Center) provides an overview of the plenary session presented by Dr Martin Dreyling at ASH 2022, discussing the role of transplant and biologics in mantle cell lymphoma. In […]

Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA)  discusses pacritinib in the potential treatment of myelofibrosis and severe thrombocytopenia. Treatment options for myelofibrosis and severe thrombocytopenia are restricted due to high occurrences of JAK inhibitor-related thrombocytopenia. The abstract entitled ‘PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s […]

Dr Stephen Ansell (Mayo Clinic, Rochester, MN, USA) discusses the challenges and unmet needs in the front-line treatment of Hodgkin lymphoma. Firstly, as a curable disease in around 75% of patients one challenge is finding a cure in more patients. Secondly, in the patients who are cured, can we minimise long-term complications such as fatigue, fertility […]

Dr William Townsend shares the latest data from the final analysis of the phase III GALLIUM study in patients with follicular lymphoma, which used the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab plus chemotherapy . The study compared rituximab-based chemotherapy with obinutuzumab-based chemotherapy in patients with previously untreated advanced-stage follicular lymphoma. The abstract ‘OBINUTUZUMAB PLUS […]

Prof Barbara Eichhorst (University Hospital Cologne, Cologne, Germany) discusses the Phase 3 GAIA/CLL13 TRIAL trial investigating venetoclax and obinutuzumab in the treatment of fit patients with CLL. The abstract ‘TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 TRIAL’ (Abstract: LB2365) […]